Hsu C.-S.JIA-HORNG KAO2021-09-042021-09-0420161139-6121https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007283924&partnerID=40&md5=ddfb031dcdcd9cf04a7d5170b2655dd4https://scholars.lib.ntu.edu.tw/handle/123456789/581923Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection are important global public health problems with shared transmission routes. Although HIV/HCV coinfection is not uncommon, the prevalence rates vary significantly across different studies and regions. In Taiwan, injection drug users have become the major contributors to the HIV/AIDS epidemic since 2005. Because the prevalence of HCV infection is high in injection drug users, this HIV epidemic is also associated with a significant increase of HIV/HCV coinfection in Taiwan. To control Taiwan’s HIV epidemic, Taiwan Centers for Disease Control (CDC) launched a harm-reduction program in 2006. The HIV epidemic, the percentage attributed to injection drug users, and the prevalence of HIV/HCV coinfection gradually declined thereafter. In this article, we aimed to thoroughly examine the current literatures of HIV/HCV coinfection in Taiwan and hope to provide a better understanding of the needs for the management of this coinfection. We conducted a narrative review and searched for literature from PubMed, Ovid MEDLINE, and the Cochrane Library database untill August 2015. Studies relevant to the epidemiology and associated risk factors of HIV/HCV coinfection in Taiwan were examined and discussed. ? Permanyer Publications 2016.Coinfection; Epidemic; Hepatitis C; HIV infection; Taiwan[SDGs]SDG3[SDGs]SDG5alanine aminotransferase; aspartate aminotransferase; gamma interferon inducible protein 10; antivirus agent; Article; CD4 lymphocyte count; disease transmission; drug abuse; hepatitis C; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; Human immunodeficiency virus prevalence; liver fibrosis; mixed infection; needle sharing; prevalence; risk factor; seroconversion; Taiwan; complication; hepatitis C; HIV Infections; mixed infection; Antiviral Agents; Coinfection; Hepatitis C; HIV Infections; Humans; Risk Factors; Taiwanjournal article274385792-s2.0-85007283924